SEC Form 4 · accession 0001144204-18-062675
Fortress Biotech, Inc. · FBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robyn Hunter
Officer — Chief Financial Officer
Period of report
Nov 23, 2018
Accepted (ET)
Nov 30, 2018 · 5:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001429260
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Nov 23, 2018 | S | 20,370 | $1.29 | D | 239,759 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1In connection with the vesting of 62,500 shares on November 20, 2018, a total of 20,370 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
- F2Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the sale transactions on November 23, 2018, was $1.28 to $1.34. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Of the 239,759 shares, 187,500 shares are restricted stock units.